APB/Molecular Dynamics Merger Hopes To Challenge Perkin-Elmer
This article was originally published in The Gray Sheet
Executive Summary
Amersham Pharmacia Biotech is hoping that its $256 mil. acquisition of Molecular Dynamics will increase sales and distribution opportunities for Molecular's MegaBACE 1000 high-throughput DNA sequencer and create a viable threat to market leader Perkin-Elmer.